Dr Reddy’s confirms Gilead licence link for once-yearly HIV prevention candidate

Dr Reddy’s Laboratories has confirmed that a media report stating it had secured a voluntary licence for Gilead Sciences’ once-yearly HIV prevention drug was accurate and related to the company’s September 17 announcement on an expanded collaboration with Gilead.

In a clarification filed with BSE Surveillance on September 18, Dr Reddy’s said the report referred to its press release titled, ‘Dr. Reddy's expands collaboration with Gilead Sciences through voluntary licensing agreement for investigational once-yearly lenacapavir for HIV prevention.’

The exchange had sought the company’s response after a report published by pharma.economictimes.indiatimes.com was captioned, ‘Dr Reddy’s gets voluntary license for Gilead’s once-yearly HIV prevention drug.’

The clarification confirms the link between the report and the prior-day company release but adds little on the commercial scope of the arrangement. Dr Reddy’s did not disclose the financial consideration, licence duration, geographic markets, manufacturing plans, regulatory pathway, launch timetable, capacity requirement or expected revenue contribution.

That leaves the immediate financial significance of the collaboration unclear. Lenacapavir remains described by the company as investigational for HIV prevention, meaning the announcement should not be read as confirmation of a near-term commercial launch or a defined earnings stream.

The arrangement nevertheless fits Dr Reddy’s stated strategy of supplementing its established generics operations with partnerships, differentiated products and selected innovative assets. The company’s Global Generics business, which spans North America, Europe, India and emerging markets, contributed 89 per cent of revenue in the first quarter of FY27. Management has been pursuing growth opportunities in biosimilars, peptides, consumer health and in-licensed products alongside its traditional generic medicines portfolio.

In the June quarter, Global Generics revenue stood at Rs 7,199 crore, while Pharmaceutical Services and Active Ingredients revenue was Rs 852 crore. The company reported broad-based underlying growth across key markets, although quarterly profitability was affected by an out-of-specification semaglutide API batch, lower lenalidomide sales and higher freight and solvent costs.

The latest licensing development is therefore strategically relevant because it potentially adds another differentiated product opportunity to Dr Reddy’s wider pipeline. However, the company has not yet provided the information needed to assess its eventual sales potential, investment requirement or margin profile.

Responding to BSE’s query on whether negotiations had taken place and whether it could provide a chronological sequence of events, Dr Reddy’s marked the response as ‘Not Applicable’. It also said there was no undisclosed information requiring disclosure under Regulation 30 of the SEBI Listing Regulations.

On possible regulatory or legal proceedings associated with the matter, the company again said ‘Not Applicable’. Dr Reddy’s further stated that the matter did not constitute a material event or information requiring separate disclosure under Regulation 30, while adding that it makes timely disclosures of events it considers material.

As of 9:25 am on September 18, 2026, Dr Reddy’s shares were trading at Rs 1,192.70, up 1.76 per cent from the previous close of Rs 1,172.05. The stock was about 13.3 per cent below its 52-week high of Rs 1,376.30 and around 5 per cent above its 52-week low of Rs 1,135.65.

Over the past year, the stock has declined 6.26 per cent, compared with a 3.73 per cent fall in the BSE 500, implying an underperformance of about 2.53 percentage points. Investors will now await further disclosures on the licence territory, regulatory plans and commercial framework to determine whether the Gilead collaboration can translate into a measurable business opportunity for Dr Reddy’s.

Disclaimer: The article is for informational purposes only and not investment advice.